Loading stock data…
$22.37-0.45 (-1.97%)
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. in the Healthcare sector is trading at $22.37 with a market capitalization of $2.5B. Wall Street consensus targets $36.20 (15 analysts), implying a +61.8% move over the next 12 months. The stock is currently 35% below its 52-week high of $34.29, remaining 1.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $284,000↑ | $141,000↑ | $132,000↓ | $70.57M↑ | $75,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$126.27M↓ | -$116.17M↑ | -$122.75M↓ | -$40.01M↑ | -$106.77M |
| Net Income | -$127.12M↓ | -$104.90M↑ | -$120.36M↓ | -$34.60M↑ | -$100.73M |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclona...